Related Experiment Videos
Interferon therapy in multiple myeloma
Abstract:
A woman with multiple myeloma relapsed after 6 years of satisfactory tumor control with melphalan therapy. When progression then occurred, she was given exogenous human leukocyte interferon, 3 x 10(6) reference units twice daily i.m., as the sole therapy. Side-effects of the interferon therapy consisted of fever reactions and thrombocytopenia. One month after the initiation of interferon therapy there was 1) improvement of general health with less pain and tiredness, 2) reduction of the M-component, IgG-lambda, in the serum, and 3) a reduced plasma cell concentration in the bone marrow. After 5 months of interferon therapy tumor progression occurred despite continuous interferon treatment. At the same time, the tumor cells were less sensitive to interferon in in vitro tests than prior to interferon therapy. It is suggested that interferon therapy should be given as initial treatment to a few patients with multiple myeloma in a phase I trial.
Insights
This case study shows that human leukocyte interferon can temporarily control multiple myeloma progression. However, tumor cells developed resistance, suggesting interferon may be best used early in treatment for multiple myeloma.
Area of Science:
- Oncology
- Immunology
Background:
- Multiple myeloma is a cancer of plasma cells.
- Melphalan is a chemotherapy drug used for multiple myeloma.
Observation:
- A patient with relapsed multiple myeloma received human leukocyte interferon therapy.
- Interferon treatment resulted in temporary symptom improvement and reduced myeloma markers.
- Side effects included fever and low platelet count (thrombocytopenia).
Findings:
- After 5 months, the multiple myeloma progressed despite continued interferon.
- In vitro tests showed decreased tumor cell sensitivity to interferon over time.
- This suggests the development of interferon resistance in multiple myeloma.
Implications:
- Interferon may have a role in managing relapsed multiple myeloma.
- Early administration of interferon in a phase I trial is proposed.
- Understanding interferon resistance mechanisms is crucial for optimizing myeloma treatment.